cyrilzakka/clinical-trials huggingface dataset:
Effect of Chlorhexidine on Bacteriuria

This study is conducted to determine and compare the effect of applying Povidone-iodine and Chlorhexidine solutions for perinea washing on bacteriuria rate and type in patients with urinary catheter in intensive care unit.

This is a double blind randomized study with control group. The population is patients in intensive care unit of Shahid Beheshti hospital of Babol city. Main include criteria are 18-55 years old, need to having urine catheter for 10 days at least and no urinary infection in catheterization time. Main exclude criteria are appearing genital wound, allergic or dermatitis disorders. Sample size include 105 patients dividing in three equal groups of Povidone-iodine, Chlorhexidine and Normal saline randomly. Interventions are Washing perinea area and catheter first 5 centimeters by 15 ml of Povidone-iodine 10%, Chlorhexidine .2% or Normal saline .9%, 3 times a day for 10 days. Urine analysis are performed in days 1,3,5,7 and 9 after catheterization and urine cultures are performed in days 5 and 10 after catheterization for detection of bacteriuria and microorganism type.

Eligibility Criteria:
Inclusion Criteria:

* Must need a urinary catheter for 10 days at least
* Must have 18-55 years old
* Men subjects must doing circumcision already
* Urinary catheter must be apply in a standard method by researcher or via her supervision

Exclusion Criteria:

* No more tendency of patient or his/her significant other for continuing study
* Malignant disease such as prostate or uterine cancer
* History of recurrent urinary infection
* Congenital urinary system disorders
* history of allergy
* Immunodeficiency disorders
* Urinary system intervention in past sixth months
* Urinary infection at study start
* Positive urine analysis or urine culture results in first 3 days of study
* Abdominal or pelvic surgery
* Women having period during study
* Any allergic reaction or dermatitis resulted from applying study solutions
* Appearing genital wounds
* Diabetes mellitus
* Wound in genital area
* Discharging, transferring or dying in first week of study
Bern Venous Stent Registry

The purpose of this study is to examine patency rates of self-expanding nitinol stents for treatment of iliofemoral and inferior vena cava residual thrombosis, obstruction or stenosis. Moreover, clinical outcome data of patients treated with these venous stents will be collected.

Background: Obstruction and stenosis of the ilio-femoro-caval veins are difficult to treat by conservative measures only. Despite anticoagulation and consequent use of compression stockings, lower extremity venous hypertension affects patients quality of life and health status by causing venous claudication, swelling, skin changes, and venous ulcers. In the last decades venous stenting has become an accepted treatment for ilio-femoro-caval obstruction. Recently, novel self-expanding nitinol stents have been specifically designed for the venous system to account for the anatomical structure of ilio-femoro-caval veins.

Gap of Knowledge: There are few data on short and long term outcomes of self-expanding Nitinol stent placement in ilio-femoro-caval veins.

Objective: To study patency rates and clinical outcome data of self-expanding Nitinol stents that were specifically designed for iliofemoral and inferior vena cava residual thrombosis, obstruction or stenosis.

Eligibility Criteria:
Inclusion Criteria:

Patients receiving self-expanding venous nitinol stents for one of the following indications:

* Residual thrombosis of iliofemoral veins and/or inferior vena cava after thrombus removal (by catheter-directed thrombolysis or pharmacomechanical thrombolysis)
* Post-thrombotic syndrome and chronic obstruction of iliofemoral veins and/or inferior vena cava
* Chronic venous insufficiency and presence of non-thrombotic venous stenosis of iliofemoral veins and/or inferior vena cava

Exclusion Criteria:

* No consent
* Inability to provide informed consent
* Allergy to Nitinol
* Pregnancy, breast-feeding or birth-giving during the last 30 days
* Life expectancy \<3 months
Patient Priorities for Survivorship Care in Older Breast Cancer Survivors

The objective of this study is to adapt the Patient Priorities Care (PPC) framework to breast cancer survivorship via a user-centered approach, through an iterative process in which patients and their physicians help to refine and modify the intervention. A second objective is to evaluate the feasibility and effectiveness of the adapted PPC framework in breast cancer survivorship for older adults.


Eligibility Criteria:
Inclusion Criteria:

* able to write and speak English
* Stage I/II/III breast cancer diagnosis
* within 3 months of active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment)
* ≥3 documented comorbidities by chart review, or taking ≥10 medications, have ≥ 1 hospitalization over the past year, ≥ 2 emergency department visits over the past year, seen by \> 2 specialists over the past year
* able to provide consent

Exclusion Criteria:

* currently on active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment)
Changes in Inflammatory Response After Immunonutrition Compared to Standard Nutrition in Colorectal Cancer Tissue

It is Randomized Controlled Trial, in which investigators will estimate the impact of the use of immunonutrition support compared to standard nutritional support in the preoperative period in patients with colorectal cancer.

The first choice of treatment in colorectal cancer is surgery. Nutritional support in form of oral nutritional supplements (ONS) in the preoperative period is widely accepted in reducing the incidence of perioperative complications and immunonutrition is generally recommended. However, there is little clinical data regarding the impact of such treatment on a tumor biology.

Investigators want to perform Randomized Controlled Trial to explore the impact of the use of immunonutrition in relation to standard nutritional support in the preoperative period on alternating the expression of inflammatory response cytokines expression and leukocytes infiltration in tumor tissue in patients operated for colorectal cancer.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of colon cancer during preoperative colonoscopy confirmed by histopathological examination.

Exclusion Criteria:

* emergency/urgent operation
* active infection
* inflammatory bowel diseases in history
* other systemic immune disorders
* the necessity of preoperative neoadjuvant treatment (radiotherapy or chemotherapy)
* metastatic disease, or local infiltration of cancer which was described as T4 stage in preoperative CT scan
* patients who were not able to intake at least 85% of administrated ONS doses
E3-Hormone Refractory Prostrate Cancer Taxotere Combination

The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Metastatic hormone refractory prostate cancer defined as those patients with evidence of progression of disease in spite of castrate levels of testosterone indicated by rising levels of PSA
* No previous chemotherapy although those patients that have received estramustine can enter the study provided the estramustine was stopped 3 weeks before dosing of study drug
* screening PSA values \>20ng/ml. this must be confirmed by two separate measurements at least 2 weeks apart

Exclusion Criteria:

* Treatment within 4 weeks before randomization and/or whilst on study, treatment with the following: 1)non-approved or experimental drug, 2)treatment with a drug with similar mechanism of action to ZD6474
* concurrent treatment with other anticancer agents, othr than docetaxel and prednisolone as defined in the protocol
Preference Study With Elderly Patients Recurrent Ovarian Cancer

Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)

Approximately 60% of all cancer diseases appear to people aged 65 years and older. Ovarian cancer is the most frequent cause of death among gynaecological malignant tumours. Since the highest carcinoma incidence is between the 60th and 70th year more women will come down with ovarian cancer because of increased life expectancy. At least 65% of patients with FIGO stage III/IV will exhibit a relapse or progress after first-line therapy. In most studies the age of the patients is limited to 65 years. It could be shown that especially elder patients often receive an inadequate operative and cytostatic therapy resulting in a worse prognosis.

Patients aged 70 years or elder who will be treated with treosulfan, given oral or intravenous, shall be compared regarding the patient compliance, toxicity especially hematological and gastrointestinal toxicity grade 3-4 (CTC NCI), overall survival, progression free survival, quality of life.

Eligibility Criteria:
Inclusion Criteria:

* patient with relapsed ovarian cancer
* study therapy of third regime
* measurable or evaluable tumor lesions or progression defined as CA-125 more than \>= 100 U/ ml.
* Age \>= 70 years
* ECOG 0-2
* written informed consent

Exclusion Criteria:

* Pretreatment with treosulfan
* patient without measurable or evaluable tumor lesions or CA-125 more than \>= 100 U/ ml.
* no adequate bone marrow function (leukocyte \<= 2,9 x 109/l, platelets \<= 100 x 109/ l
* creatinin and bilirubin within \>= 1,25 x fold of the reference laboratory´s normal range
* simultaneous radiotherapy
Project Bidof - Monovision by Pairing Bifocal and EDOF Lens

Modern day cataract surgery isn't just a rehabilitative procedure anymore but rather aims at improving a patient's quality of life by reducing the need for spectacles in everyday life to a minimum. One way of achieving this goal is by using different lens technologies, such as a mono- or bifocal lens paired a lens with EDOF technology, as EDOF lenses provide an enhanced depth of focus by creating a single elongated focal point. As this method is well established, the aim of this study is to compare the monofocal/EDOF cohort to the bifocal/EDOF cohort and evaluate visual acuity and patient satisfaction for both combinations.


Eligibility Criteria:
Inclusion Criteria:

* Age between 21 and 99 years
* signed informed consent form
* condition after cataract surgery

Exclusion Criteria:

* no signed informed consent form
* laser treatment of the Cornea
* macular pathologies
* corneal pathologies
* irregular astigmatism
* pregnancy
Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients

At present, there are no FDA-approved treatments for chemotherapy-induced neuropathy. Discrete neuro anti-inflammatory effects of metformin support its repurposing as a neuroprotective agent in patients with neurodegenerative diseases. Therefore, this study aims to evaluate the effect of metformin on the amelioration of paclitaxel induced neuropathy in cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (\>18 years old)
* Early-stage breast cancer patients who will receive adjuvant paclitaxel
* Performance status according to Eastern Cooperative oncology group (ECOG) \< 2.
* Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count ≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine\<1.5 mg/dl).

Exclusion Criteria:

* Clinical neuropathy at prior to enrollment.
* Patients treated with medications that increase the risk of neuropathy like amiodarone, Colchicine, metronidazole, phenytoin.
* Patients with a history of hypersensitivity to metformin.
* Pregnant or lactating females.
* Patients who are using metformin for any other cause.
* Patients with Diabetes mellitus.
* Receiving vitamin B1, B6, B12 or another vitamin supplemental therapy.
* Receiving antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, clonazepam, or mexiletine), topical analgesics, and amifostine.
Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer(NSCLC) is the leading cause of death in Korean men after stomach cancer. Surgical resection plays a main role for curative treatment. However, less than 20 % of the NSCLC patients have been found in stage I-II disease. In inoperable stage IIIA/B disease, the recommended treatment is combined chemotherapy and radiation therapy. Various kinds of combination of 2 modalities have been used either in sequential or concurrent setting. Concurrent chemoradiotherapy(CCRT) have been recognized to have better survival than radiation therapy alone or sequential therapy, but additional consolidation chemotherapy after CCRT is not yet to be determined for the beneficial role in survival gain. Docetaxel is an anticancer drug and has synergistic anticancer effect in various cancer with cisplatin, another anticancer drug. In the present study, randomised trial will be performed to confirm the efficacy of the consolidation chemotherapy with docetaxel and cisplatin after completing CCRT with the same chemotherapeutic agents in stage III inoperable NSCLC on progression free survival and overall survival.


Eligibility Criteria:
Inclusion Criteria:

* Histologically proven non-small cell lung cancer
* Presence of measurable disease by RECIST
* Inoperable Stage IIIA or IIIB, proven by CT or MRI (except wet T4). However, N2 or N3 should be confirmed by PET or pathology. (For T4, PET is optional)
* 18 years of age or older
* ECOG Performance status 0-1
* No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy
* Serum Hgb ≥ 10 gm/dL, platelet ≥ 100,000/μL, absolute neutrophil count ≥ 1,500/μL
* Serum creatinine ≤1.25 x UNL or creatinine clearance ≥60 mlmL/min
* Serum bilirubin ≤ 1.5 x UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL, alkaline phosphatase ≤ 5 x UNL
* FEV1\> 0.8 L
* Patients must sign an informed consent

Exclusion Criteria:

* Carcinoid tumor, small cell carcinoma of lung
* Patients with any distant metastasis
* History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix
* Any other morbidity or situation with contraindication for chemotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment)
* Pregnant or lactating women, women who has not taken test of pregnancy (within 14 days before the first administration) and pregnant women
* Women and men of childbearing potential who have no willing of employing adequate contraception
Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)

The main aim of this study is to test whether cognitive behavior therapy could be effective in treating obsessive compulsive disorder. Here, the investigators test the in group effects of a 15 week long treatment delivered via the Internet for residents in Stockholm County.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with Obsessive compulsive disorder according to the DSM criteria
* Be at least 18 years old
* YBOCS \>7

Exclusion Criteria:

* other primary diagnosis
* substance abuse,
* psychosis,
* bipolar disorder,
* suicidal ideation,
* adjusted pharmacological treatment the last two months
* current psychological treatment for OCD,
* been treated with CBT the last two years,
* serious somatic disease,
* Y---BOCS\>31
* hoarding as primary OCD subtype
PACE Vape Messaging Study

The purpose of this study is to examine the effect of exposure to vape education messages on beliefs, perceptions, norms, and behaviors related to electronic vapor product use.

Using content developed from the formative research phase, participants in this randomized controlled trial will either be exposed to ten vape education messages or to ten messages on sun safety, with all messages formatted for social media.

This study will take place over a 1-month period. Individuals who complete the screening survey and are eligible to participate will be invited to complete a 10-15 minute baseline survey at the start of the study. This survey will ask questions about tobacco and electronic vapor product use, and beliefs about and perceptions of vape products. This survey will also ask about exposure to tobacco and e-cigarette marketing, exposure to prevention messaging on vaping and tobacco use, and peer and family influences on tobacco use. During the survey, participants will be presented with and be asked to provide feedback for short health-related messages.

One month after completing this survey, participants will be sent an invitation to the follow-up survey. This survey will again ask about tobacco and electronic vapor product use, and beliefs about and perceptions of vape products.

All study procedures will take place remotely, with surveys conducted online. At the end of the first survey, participants will be eligible to receive a $10 online gift card. Upon completion of the follow-up survey, participants will be eligible to receive a $15 online gift card. In total, participants will be eligible to receive up to $25 for completing both surveys. Those who are ineligible will not be asked to complete the baseline survey and will not be compensated.

Eligibility Criteria:
Inclusion Criteria:

* Ages 18-24
* Vermont resident
* Access to a smartphone with internet
* Use of one or more social media site(s) at least weekly

Exclusion Criteria:

* Aged 25 years or older
* Not Vermont resident
* No access to a smartphone with internet
* Use of one or more social media site(s) less than weekly
A Safety Study of 212Pb-Pentixather Radioligand Therapy

This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.

This is a study to determine what dose is acceptably safe for further testing.

In this study, participants are asked to:

* undergo SPECT/CT imaging with Lead-203 Pentixather (a radiotracer) to ensure the tumor lesions have the needed receptors
* undergo serial blood sampling for during and after the SPECT/CT scan for radiation and dosimetry calculations (to determine how much of the Lead-212 Pentixather to administer)
* receive up to 2 infusions of arginine \& lysine as a kidney protectant
* receive up to 2 infusions of Lead-212 Pentixather, 6 weeks between each infusion
* undergo imaging at 3 months post treatment to determine disease response

Eligibility Criteria:
Inclusion Criteria:

* ability to provide independent consent
* adequate bone marrow function (platelet count ≥ 100,000; hemoglobin of ≥ 10 g/dL; neutrophil count ≥ 1,500 cells/mm3)
* adequate kidney function (creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault equation
* adequate liver function (serum bilirubin ≤ 3x the upper limit of normal, AST ≤ 5x the upper limit of normal, and ALT ≤ 5x the upper limit of normal)
* failed initial therapy or declined further therapy known to confer benefit
* have at least one lesion ≥ 2 cm that is positive for CXCR4 as demonstrated by Lead-203 Pentixather SPECT/CT

Exclusion Criteria:

* major surgery within 4 weeks of consent
* antoher investigational agent within 4 weeks of consent
* uncontrolled illness including, but not limited to, ongoing or active infection that would necessitate a delay in therapy or cause a hospital admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic cirrhosis or severe impairment, or psychiatric illness/social situations that would limit compliance with study requirements.
* prior solid organ transplant
* cytotoxic or antineoplastic therapy within 21 days of consent (42 days for nitrosoureas)
* antibody therapy within the 21 days of consent
* allogenic bone marrow or stem cell transplant, or any stem cell infusion, within 84 days of consent
* pregnancy
* breastfeeding
* refusal to comply with birth control requirements during study
Novel Device for Rapid Fluid Administration

The aim of the study is to determine if a new device is more effective in fluid administration than devices currently used when resuscitating pediatric patients in septic shock. This study will take place in a simulation lab setting and will not include the use of patients.

In this study, participants will be randomized to one of three devices in a Pediatric Intensive Care Unit simulation setting. Each participant will be provided the device, a 1L NS bag, tubing and a 22g IV. In each scenario, the objective will be to administer 3 20cc/kg boluses within a 15 minute period to the simulated patient.

Eligibility Criteria:
Inclusion Criteria:

* Pediatric emergency medicine or pediatric intensive care unit nurses, pediatric residents, medics and attendings.

Exclusion Criteria:

* Inability to operate equipment due to illness or physical impairment.
Same-day Radioembolization for Large HCC

In patients who has no sign suggesting high lung shunt fraction (TIPS, hepatic vein invasion, hepatic vein enhancement on arterial phase, dysmorphic intratumoral vessel), planning angiography, MAA scan, and radioembolization are performed in a single day with SIR-Spheres. This prospective registry will prove that the selection criteria is accurate and same-day radioembolization is feasible and safe.


Eligibility Criteria:
Inclusion Criteria:

* HCC can be diagnosed by AASLD guideline
* hepatocellular carcinoma 5cm or larger
* dysmorphic intratumoral vessels 3mm or smaller
* Child-Pugh class A
* ECOG 0 or 1
* the following lab should be met. A. Leukocytes ≥ 1,000/µL and ≤ 20,000/µL B. Hemoglobin ≥ 6.0 g/dL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg/dL D. Platelet ≥ 40,000/µL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg/dL (if patient is receiving hemodialysis, no upper limit of creatinine)

Exclusion Criteria:

* hepatic vein invasion on CT/MRI
* hepatic vein enhancement on arterial phase of CT/MRI
* TIPS
* dysmorphic intratumoral vessels \> 3mm
* main portal vein invasion
* significant COPD or interstitial lung disease
The Value of Enhanced External Counterpulsation on Erectile Dysfunction

The purpose of this study is to investigate the efficacy of Enhanced External Counterpulsation (EECP) in patients with erectile dysfunction

Patients with erectile dysfunction will be randomized into two groups: EECP intervention or not. Erectile function, hemodynamic parameters, vascular endothelial function will be measured and compared.

Eligibility Criteria:
Inclusion Criteria:

1. men over 18 years old;
2. provide signed informed consent;
3. existence of erectile dysfunction
4. agree not to use any other erectile dysfunction treatment at least one month;

Exclusion Criteria:

1. history of long drug abuse;
2. pelvic, spine, brain trauma or surgery;
3. endocrine, liver, lung, kidney disease, malignancies, hematological disorders;
4. abnormal urogenital status, such as small testicle (\<2cm), penile plaques;